Patient-reported outcomes enhance understanding of the impact of pazopanib in soft tissue sarcoma.

Corneel Coens, Winette T. A. van der Graaf, Jean-Yves Blay, Sant P. Chawla, Ian Judson, Roberta Sanfilippo, Stephanie C. Manson, Rachel A. Hodge, Sandrine Marreaud, Judith B. Prins, Iwona Lugowska, Saskia Litière, Andrew Bottomley, Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072). Cancer. ,vol. 121, pp. 2933- 2941 ,(2015) , 10.1002/CNCR.29426

Ethan Basch, Beyond the FDA PRO Guidance: Steps toward Integrating Meaningful Patient-Reported Outcomes into Regulatory Trials and US Drug Labels Value in Health. ,vol. 15, pp. 401- 403 ,(2012) , 10.1016/J.JVAL.2012.03.1385

Guilherme Nader Marta, Luís G Del Nero, Gustavo Nader Marta, Andrea Mangabeira, Gabriela Critchi, Maria J Kovacs, João Luis Fernandes da Silva, Everardo D Saad, None, Treatment priorities in oncology: do we want to live longer or better? Clinics. ,vol. 69, pp. 509- 514 ,(2014) , 10.6061/CLINICS/2014(08)02

Carolyn C. Gotay, Crissy T. Kawamoto, Andrew Bottomley, Fabio Efficace, The Prognostic Significance of Patient-Reported Outcomes in Cancer Clinical Trials Journal of Clinical Oncology. ,vol. 26, pp. 1355- 1363 ,(2008) , 10.1200/JCO.2007.13.3439

Carla DeMuro, Marci Clark, Lynda Doward, Emily Evans, Margaret Mordin, Ari Gnanasakthy, Assessment of PRO Label Claims Granted by the FDA as Compared to the EMA (2006–2010) Value in Health. ,vol. 16, pp. 1150- 1155 ,(2013) , 10.1016/J.JVAL.2013.08.2293

Jordan Amdahl, Stephanie C. Manson, Robert Isbell, Ayman Chit, Jose Diaz, Lily Lewis, Thomas E. Delea, Cost-Effectiveness of Pazopanib in Advanced Soft Tissue Sarcoma in the United Kingdom Sarcoma. ,vol. 2014, pp. 481071- 481071 ,(2014) , 10.1155/2014/481071

Ateesha F. Mohamed, A. Brett Hauber, Maureen P. Neary, Patient benefit-risk preferences for targeted agents in the treatment of renal cell carcinoma. PharmacoEconomics. ,vol. 29, pp. 977- 988 ,(2011) , 10.2165/11593370-000000000-00000

Robin Matsuyama, Sashidhar Reddy, Thomas J. Smith, Why Do Patients Choose Chemotherapy Near the End of Life? A Review of the Perspective of Those Facing Death From Cancer Journal of Clinical Oncology. ,vol. 24, pp. 3490- 3496 ,(2006) , 10.1200/JCO.2005.03.6236

Melanie Calvert, Jane Blazeby, Douglas G. Altman, Dennis A. Revicki, David Moher, Michael D. Brundage, for the CONSORT PRO Group, Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. ,vol. 309, pp. 814- 822 ,(2013) , 10.1001/JAMA.2013.879

D. Cella, A.S. Pickard, M.S. Duh, A. Guerin, N. Mishagina, L. Antràs, M.P. Neary, L. McCann, R. Hodge, C.N. Sternberg, Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial European Journal of Cancer. ,vol. 48, pp. 311- 323 ,(2012) , 10.1016/J.EJCA.2011.05.017